Friday, September 4, 2026 See who Washington just made rich Get the free brief →
Money Racket
Who Cashes In When Washington Moves
HEALTHCARE & FDAFDA Approves First Alexander Disease DrugtodayTRADE & TARIFFSAmazon Pockets $600M Tariff Refund—Retail Rivals Face Margin Squeeze4 weeks agoWHITE HOUSEFinCEN Tightens Southwest Border Money ReportingtodayHEALTHCARE & FDAHHS Boosts Hospital Payments by $2 Billion—Acute Care Operators Win4 weeks agoDEFENSEPratt & Whitney Engine Flaw Drives MRO WorkloadyesterdayHEALTHCARE & FDACMS Ends Medicare Part D Subsidy—Drug Plan Insurers Face Margin Pressure4 weeks agoDEFENSEAirbus Landing Gear Flaw Expands MRO WorkloadyesterdayHEALTHCARE & FDACMS Raises IRF Payments for 2027—Rehab Hospitals Get Relief4 weeks agoTECHDHS Awards AWS $60M Cloud Hosting DealyesterdayTRADE & TARIFFSTrump Administration Hits $100B Tariff Refund Milestone4 weeks agoWHITE HOUSEGardaWorld Wins $100M ICE Armed Transport DealyesterdayDEFENSERising Defense Spending Lifts Northrop Grumman Outlook4 weeks agoENERGYNASA Awards Sierra Lobo $77M for Space ReactoryesterdayMARKETSFTC Threatens Booking Holdings Over Priceline Practices4 weeks agoTECHAccenture Wins $30M DOE Modernization Contract2 days agoHEALTHCARE & FDAFTC Sues Hims & Hers Over Privacy and Billing Practices4 weeks agoDEFENSETrump Scales Back Korea Exercises—Defense Contractors Face Uncertainty2 days agoHEALTHCARE & FDAFDA Approves Tudriqev for Advanced Melanoma4 weeks agoWHITE HOUSETrump Bans Foreign Grid Equipment—US Suppliers Win2 days agoTRADE & TARIFFSRetailers Sell Off Tariff Refund Rights for Cash—Windfall Monetized Before Payout4 weeks agoENERGYDOE Stays Clean Energy Building Rules—Fossil Fuel Lobby Wins Reprieve2 days agoTECHU.S. Signs $874M Semiconductor Research LOIs—Chip Makers Get Federal Backing4 weeks agoHEALTHCARE & FDAFDA Approves Lisraya for Dermatomyositis—Rare-Disease Win3 days agoWHITE HOUSEDHS Tightens H-1B/L-1 Visa Fees—Tech Hiring Costs Rise for Employers4 weeks agoMARKETSFDIC Eases Reciprocal Deposit Rules—Bank Funding Win3 days agoENERGYMichigan Court Rejects Enbridge Line 5 Permit Under Great Lakes4 weeks agoMARKETSFTC Sues Amazon Over Ad Auction Manipulation—Antitrust3 days agoDEFENSEPentagon Awards Space-Based Target Tracking Contracts4 weeks agoENERGYTrump Admin Fast-Tracks Alaska Oil Pipeline—Energy Win3 days agoTECHTrump Administration Adds 6 Chipmakers to U.S. Portfolio4 weeks agoCRYPTOSEC Proposes Tailored Crypto Offering Rules—Clarity Win3 days agoWHITE HOUSEWhite House Drafts Vaccine-Autism Order—Pharma Faces Uncertainty4 weeks agoDEFENSEBoeing Wins $131B F-15 Contract—Fighter Jet Dominance4 days agoDEFENSETrump Pushes $1.5T Defense Budget—Lockheed, RTX, GD Lock in Gains4 weeks agoCRYPTOSEC Proposes Crypto Offering Exemptions—Regulatory Clarity4 days agoWHITE HOUSETrump Order Splits MMR Vaccine—Pharma Faces Demand Shift3 weeks agoENERGYCentrus HALEU Enrichment Wins Policy Tailwind—Nuclear Fuel4 days agoWHITE HOUSETrump Orders Childhood Vaccine Schedule Spacing3 weeks agoHEALTHCARE & FDAWhat Is a PDUFA Date?4 days agoHEALTHCARE & FDAFDA Updates Fresh-Cut Produce Safety Guidance3 weeks agoMARKETSWhat Is a Negotiated Price4 days agoENERGYNRC Approves NAC MAGNASTOR Spent Fuel Storage Cask3 weeks agoHEALTHCARE & FDAFDA Approves Mimrylo for Polycythemia Vera6 days agoHEALTHCARE & FDAFDA Clears Screwworm Prevention Drug for U.S. Livestock3 weeks agoHEALTHCARE & FDAFDA Authorizes Generic Bimectin for Screwworm Prevention6 days agoDEFENSEIonQ Lands $28M U.S. Defense Quantum Contract3 weeks agoHEALTHCARE & FDAFDA Opens GenAI Medical Device Regulation to Public Input6 days agoTECHFCC Eases Broadband Label Rules—ISPs Win Flexibility3 weeks agoHEALTHCARE & FDATrump Admin Blocks $1.6B in Fraudulent Medicare Lab Payments6 days agoDEFENSEBlackSky Lands Multi-Year Satellite Contract3 weeks agoTECHNHTSA Extends Comment Period on Vehicle Safety Exemptions6 days agoHEALTHCARE & FDASimparica Trio Gets Screwworm EUA—Zoetis Wins3 weeks agoENERGYBLM Launches 30-Year Permit for Trans-Alaska Pipeline Operationslast weekTRADE & TARIFFSTrump Tariffs on Drones Boost U.S. Makers3 weeks agoMARKETSFTC Blocks Henkel's $725M Liquid Nails Bid—Antitrust Winslast weekTRADE & TARIFFSKimberly-Clark Pockets $45M Tariff Refund3 weeks agoHEALTHCARE & FDAFDA Approves First RAS Inhibitor for Pancreatic Cancerlast weekCRYPTOSEC Delays Crypto Rules—Uncertainty Persists3 weeks agoDEFENSEBoeing Lands $131B F-15 Contract—Fighter Jet Dominancelast weekTRADE & TARIFFSTariff Refunds Turbocharge Retailer Earnings3 weeks agoHEALTHCARE & FDACostco Enters Medicare Advantage—Retail Disruption Loomslast weekENERGYArmy Corps Permits Line 5 Tunnel—Michigan Blocks Path3 weeks agoTRADE & TARIFFSTrump's 50% Canada Tariffs Take Effect—Retailers Bracelast weekTRADE & TARIFFSTariff Refunds Flow to Retailers—Earnings Boost3 weeks agoTRADE & TARIFFSU.S. Rolls Out Iran Sanctions—Oil Prices Sliplast weekHEALTHCARE & FDACMS Ends Medicare Part D Subsidy—Insurers Face Pressure3 weeks agoHEALTHCARE & FDAAbbott's Dual Glucose-Ketone Monitor Wins FDA Nodlast weekWHITE HOUSETrump Vaccine Spacing Order Reshapes Pharma Demand3 weeks agoHEALTHCARE & FDARegeneron's Gene Therapy Wins First GSD Type Ia Approvallast weekENERGYEPA Exempts Calcium Carbonate From Pesticide Tolerance—Farm Input Eases2 weeks agoDEFENSEStryker Lands $100M Defense Contract—Combat Vehicle Boostlast weekDEFENSETrump's $1.5T Defense Push Fuels Colorado Contractor Windfall2 weeks agoTRADE & TARIFFSWalmart Deploys $2.9B Tariff Refund Into Price Cutslast weekHEALTHCARE & FDAFTC Probes Epic Systems Over Health Records Monopoly2 weeks agoTRADE & TARIFFSTrump Lifts Ground Beef Tariffs—Ranchers Face Price Pressurelast weekHEALTHCARE & FDAFDA Reclassifies Cancer Tests—Easier Path for Diagnostics2 weeks agoWHITE HOUSETrump Kills Affirmative Action Rules—Contractors Face Compliance Shiftlast weekTECHCommerce Eases Drone Export Rules—U.S. Makers Win2 weeks agoHEALTHCARE & FDAFDA Clears Robotic Blood Draw—Phlebotomy Shortage Easeslast weekDEFENSERTX Lands Fresh Missile Defense Contract—Stock Undervalued2 weeks agoWHITE HOUSELabor Dept Eases Disability Hiring Rules—Contractors Save Compliance Costslast weekENERGYNewsom Passes Diablo Canyon Decision to Successor2 weeks agoWHITE HOUSELabor Dept Eases Veteran Hiring Rules—Contractors Cut Compliancelast weekHEALTHCARE & FDAGAO Finds $7.6B Medicare Hospice Overpayment2 weeks agoTECHCHIPS Act Transforms Binghamton Into Semiconductor Hublast weekWHITE HOUSEFinCEN Finalizes BOI Exemption for U.S. Personslast weekTRADE & TARIFFSTrump Administration Targets Iran's Banking System With New Sanctionslast weekENERGYFederal Court Orders Enbridge Line 5 Removallast weekTECHUtah Governor Signs Quantum Computing Initiative Orderlast weekENERGYEnbridge Wins Federal Permit for Line 5 Tunnellast weekDEFENSEFAA Engine Inspection Order Lifts MRO Stockslast weekTECHD-Wave Wins Canadian Quantum Funding for Annealinglast weekTRADE & TARIFFSTariff Refunds Turbocharge Retailer Earningslast weekHEALTHCARE & FDATrump Vaccine Spacing Order Reshapes Pharma Demandlast week
Healthcare & FDA

FDA Approves First Alexander Disease Drug

Rare neurological disorder gets its first approved therapy, opening a small but meaningful market.

Image: Money Racket
By at Money Racket · Sep 4, 2026

The FDA approved Zanvastro (zilganersen) injection for Alexander disease, a rare progressive neurological disorder caused by mutations in the gene that produces glial fibrillary acidic protein. This is the first FDA-approved treatment for the condition and the first therapy to directly target the protein buildup driving the disease.

Free alerts

Free: catalyst alerts, straight to your inbox.

Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

The first therapy to directly target the protein buildup that drives Alexander disease opens a small but meaningful rare-disease market.

The approval benefits Reata Pharmaceuticals (verify ticker), the developer, which gains its first marketed rare-disease asset and a foothold in the neurology space. Rare-disease approvals typically command premium pricing and lower competition, though the patient population is small—Alexander disease affects fewer than 1,000 people in the US. Reata's stock has limited upside from this single indication but signals execution capability in gene therapy.

No direct competitor is exposed here; the market was previously unserved. The risk is reimbursement: CMS and private insurers will scrutinize pricing on a therapy for a rare, pediatric-onset disease with no prior standard of care. If Reata prices aggressively, payers may deny or restrict coverage, capping uptake.

Watch for Reata's pricing announcement and the first CMS coverage determination. If the company prices above $500,000 annually, expect pushback from patient-advocacy groups and payers, which could signal trouble for future rare-disease launches.

Source: original report ↗

Knowing who cashed in is only half the trade.

Every catalyst has a second move — the supplier, the sector, the part already priced in. Money Racket Pro hands you that read on every policy event, plus the pre-market brief six mornings a week, before the open.

Get the edge · $40/mo

Join the readers who get there before the financial press. Cancel anytime, one click.

Share

https://moneyracket.com/article/fda-approves-zanvastro-alexander-disease/

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Money Racket Pro

    By the time it's news, the money's already moved.

    The contract award, the executive order, the tariff cut — it mints winners before the financial press connects the dots. Pro gets you there first: what happened, who cashes in, and exactly what to watch — in a two-minute read.

    Get the free brief The policy-to-profit brief. Cancel anytime.
    The pre-market brief · Mon–Sat, 7:45am ET Get the free brief →